Literature DB >> 32110670

Cutaneous nodules and a novel GNAS mutation in a Chinese boy with pseudohypoparathyroidism type Ia: A case report and review of literature.

Yun-Ling Li1, Ting Han2, Fang Hong3.   

Abstract

BACKGROUND: Pseudohypoparathyroidism type Ia (PHP Ia) is a rare hereditary syndrome, and patients with early PHP Ia are generally not diagnosed based on the presentation of cutaneous nodules as the main clinical feature. Here, we describe a Chinese boy with PHP Ia in whom the main clinical feature was cutaneous nodules, and the patient exhibited a novel GNAS mutation. CASE
SUMMARY: A 5-year-old boy presented with a 5-year history of cutaneous nodules scattered over his entire body. The patient had a short stature, round face, short neck, and slightly flattened nose; he also had multiple hard papules and cutaneous nodules scattered over his entire body. The patient had a significantly elevated parathyroid hormone level. His serum calcium level was reduced, while his serum phosphorus level was increased and his serum thyroid-stimulating hormone level was elevated. Skin biopsy showed osteoma cutis in subcutaneous tissue. Sanger sequencing revealed a frameshift mutation, c.399delT (p.Ser133Argfs*2) in exon 5 of the GNAS gene. The patient was diagnosed with PHP Ia and subclinical hypothyroidism. He was given 1,25-dihydroxyvitamin D, calcium carbonate, and synthetic L-thyroxine. After 3 months of treatment, the patient's parathyroid hormone level decreased, and his serum calcium and serum phosphorus levels were normal. Moreover, his thyroid-stimulating hormone level decreased.
CONCLUSION: These findings can help dermatologists to diagnose PHP Ia in patients with cutaneous nodules as the main early clinical feature. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Case report; Cutaneous nodules; GNAS; Pseudohypoparathyroidism; Pseudohypoparathyroidism type Ia

Year:  2020        PMID: 32110670      PMCID: PMC7031840          DOI: 10.12998/wjcc.v8.i3.587

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  32 in total

Review 1.  Hormone resistance caused by mutations in G proteins and G protein-coupled receptors.

Authors:  A M Spiegel
Journal:  J Pediatr Endocrinol Metab       Date:  1999-04       Impact factor: 1.634

2.  Hypothyroidism in patients with pseudohypoparathyroidism type Ia: clinical evidence of resistance to TSH and TRH.

Authors:  Anne-Sophie Balavoine; Miriam Ladsous; Fritz-Line Velayoudom; Virginie Vlaeminck; Catherine Cardot-Bauters; Michèle d'Herbomez; Jean-Louis Wemeau
Journal:  Eur J Endocrinol       Date:  2008-10       Impact factor: 6.664

3.  Intragenic GNAS deletion involving exon A/B in pseudohypoparathyroidism type 1A resulting in an apparent loss of exon A/B methylation: potential for misdiagnosis of pseudohypoparathyroidism type 1B.

Authors:  Eduardo Fernandez-Rebollo; Beatriz García-Cuartero; Intza Garin; Cristina Largo; Francisco Martínez; Concepcion Garcia-Lacalle; Luis Castaño; Murat Bastepe; Guiomar Pérez de Nanclares
Journal:  J Clin Endocrinol Metab       Date:  2009-12-11       Impact factor: 5.958

4.  GNAS defects identified by stimulatory G protein alpha-subunit signalling studies in platelets.

Authors:  Kathleen Freson; Benedetta Izzi; Veerle Labarque; Monique Van Helvoirt; Chantal Thys; Christine Wittevrongel; Marie Bex; Roger Bouillon; Nathalie Godefroid; Willem Proesmans; Francis de Zegher; Jaak Jaeken; Chris Van Geet
Journal:  J Clin Endocrinol Metab       Date:  2008-09-23       Impact factor: 5.958

Review 5.  Pseudohypoparathyroidism: current concepts.

Authors:  N A Breslau
Journal:  Am J Med Sci       Date:  1989-08       Impact factor: 2.378

6.  Brachydactyly in 14 genetically characterized pseudohypoparathyroidism type Ia patients.

Authors:  Luisa de Sanctis; Sergio Vai; Maria Rita Andreo; Damiano Romagnolo; Leandra Silvestro; Carlo de Sanctis
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

7.  Pseudohypoparathyroidism type Ia and pseudo-pseudohypoparathyroidism: the growing spectrum of GNAS inactivating mutations.

Authors:  Francesca Marta Elli; Luisa deSanctis; Barbara Ceoloni; Anna Maria Barbieri; Paolo Bordogna; Paolo Beck-Peccoz; Anna Spada; Giovanna Mantovani
Journal:  Hum Mutat       Date:  2013-01-18       Impact factor: 4.878

Review 8.  GNAS mutations and heterotopic ossification.

Authors:  Murat Bastepe
Journal:  Bone       Date:  2017-09-06       Impact factor: 4.398

9.  Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS-based heterotopic ossification.

Authors:  N S Adegbite; M Xu; F S Kaplan; E M Shore; R J Pignolo
Journal:  Am J Med Genet A       Date:  2008-07-15       Impact factor: 2.802

10.  A positive genotype-phenotype correlation in a large cohort of patients with Pseudohypoparathyroidism Type Ia and Pseudo-pseudohypoparathyroidism and 33 newly identified mutations in the GNAS gene.

Authors:  Susanne Thiele; Ralf Werner; Joachim Grötzinger; Bettina Brix; Pia Staedt; Dagmar Struve; Benedikt Reiz; Jennane Farida; Olaf Hiort
Journal:  Mol Genet Genomic Med       Date:  2014-12-04       Impact factor: 2.183

View more
  3 in total

1.  Early Diagnosis of Pseudohypoparathyroidism before the Development of Hypocalcemia in a Young Infant.

Authors:  Su Kyeong Hwang; Ye Jee Shim; Seung Hwan Oh; Kyung Mi Jang
Journal:  Children (Basel)       Date:  2022-05-15

2.  Characterizing Cerebral Imaging and Electroclinical Features of Five Pseudohypoparathyroidism Cases Presenting with Epileptic Seizures.

Authors:  Zijuan Qi; Zhensheng Li; Quwen Gao; Li Dong; Jian Lin; Kairun Peng; Wei Xiang; Bingmei Deng
Journal:  Behav Neurol       Date:  2022-08-12       Impact factor: 3.112

3.  Response to trametinib in a nonsmall cell lung cancer patient with osimertinib resistance harboring GNAS R201C and R201H mutations: a case report.

Authors:  You Lv; Chao Zhou; Zhonghai Chen; Xiaokai Zhao; Yonghua Sun; Jieyi Li; Ziying Gong; Daoyuan Zhang; Hai Huang
Journal:  Anticancer Drugs       Date:  2022-08-09       Impact factor: 2.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.